Arcellx closes $200M Gilead investment and license amendment with Kite

Arcellx, Inc.

Closed transactions: issued 3,242,542 shares to Gilead for $200 million aggregate.
Includes amendment to Collaboration and License Agreement with Kite Pharma (Gilead).
Closing followed expiration of HSR waiting period under antitrust rules.
Shares issued on December 28, 2023; previously announced November 15, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.